Today: 7 February 2026
Subscribe
Browse Category

LSE:FUTR News 4 December 2025 - 22 January 2026

Future plc (FUTR) Hikes Dividend Fivefold and Launches New Buyback After Tough 2025 – Analysts Still See Big Upside

Future plc (FUTR) Hikes Dividend Fivefold and Launches New Buyback After Tough 2025 – Analysts Still See Big Upside

Future plc (LSE: FUTR), the UK-based specialist media and Go.Compare owner, has reported a drop in revenue and profit for the year to 30 September 2025 – but paired the weaker headline numbers with aggressive shareholder returns, a confident outlook for 2026 and a sizeable valuation gap versus analysts’ price targets. MarketScreener+2Shares Magazine+2 On 4 December 2025, the group unveiled full-year results, a fivefold dividend increase, a fresh £30 million share buyback and a board succession plan, triggering a sharp rebound in the share price from depressed levels. Full-year 2025 results: revenue down, margin intact For FY 2025, Future reported
4 December 2025
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop